Pendal Group LTD Autolus Therapeutics PLC Transaction History

Pendal Group LTD

$12.2 Billion
Q4 2022

A detailed history of Pendal Group LTD transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Pendal Group LTD holds 1,733,391 shares of AUTL stock, worth $3.71 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

1,733,391

Previous 1,370,757 26.46%

Holding current value

$3.71 Million

Previous $2.93 Million 12.27%

% of portfolio

0.03%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 19, 2023	BUY	$1.74 - $3.27 $630,983 - $1.19 Million	362,634 Added 26.46%	1,733,391 $0
Q3 2022 Oct 18, 2022	BUY	$2.04 - $3.76 $10,869 - $20,033	5,328 Added 0.39%	1,370,757 $2.93 Million
Q2 2022 Jul 25, 2022	SELL	$2.04 - $4.68 $19,741 - $45,288	-9,677 Reduced 0.7%	1,365,429 $3.86 Million
Q1 2022 Apr 25, 2022	SELL	$3.52 - $5.46 $245,329 - $380,540	-69,696 Reduced 4.82%	1,375,106 $5.73 Million
Q4 2021 Jan 18, 2022	BUY	$5.1 - $7.0 $186,073 - $255,395	36,485 Added 2.59%	1,444,802 $7.5 Million
Q3 2021 Nov 05, 2021	BUY	$5.32 - $7.37 $4.66 Million - $6.45 Million	875,067 Added 164.1%	1,408,317 $9.23 Million
Q2 2021 Jul 28, 2021	BUY	$4.78 - $7.96 $1.97 Million - $3.28 Million	411,685 Added 338.65%	533,250 $4.6 Million
Q1 2021 May 24, 2021	BUY	$5.49 - $9.36 $667,391 - $1.14 Million	121,565 New	121,565 $1.05 Million
Q1 2021 May 03, 2021	SELL	$5.49 - $9.36 $276,443 - $471,313	-50,354 Closed	0 $0
Q4 2020 Jan 21, 2021	BUY	$8.13 - $12.79 $409,378 - $644,027	50,354 New	50,354 $450,000

Others Institutions Holding AUTL

# of Institutions

110

Shares Held

163M

Call Options Held

2.8K

Put Options Held

13.4K

View Full List

About Autolus Therapeutics plc

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $195M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

More about AUTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pendal Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Pendal Group LTD with notifications on news.

Account